Business
Pharma, WHO team up to create permanent ‘pandemic’ market for mandated, experimental vaccines
From LifeSiteNews
By Brenda Baletti, Ph.D., The Defender
Unlimited Hangout journalist Max Jones details how Big Pharma is using the WHO to restructure the drug market, so inadequately tested vaccines and other drugs will face minimal regulation and entire populations can be compelled to take them each time the WHO declares another global pandemic.
Big Pharma and its key investors are rolling out a new strategy — “the full takeover of the public sector, specifically the World Health Organization (WHO), and the regulatory system that now holds the entire market hostage” — according to a new investigative report by Unlimited Hangout’s Max Jones.
What’s behind the new strategy? The pharmaceutical industry is facing a “patent cliff” by 2030, as many of its blockbuster drugs are set to lose their patent protection, placing $180 billion in sales at risk and threatening to topple the industry.
According to Jones, for years, when patents expired on profitable drugs, pharmaceutical giants deployed a “mergers and acquisitions” strategy, buying up smaller drug companies to add to their product portfolios.
As a result, the industry is now dominated by a handful of companies, conventional chemical drugs exist for most health issues, and the regulatory process for new ones has become onerous.
Big Pharma has now pivoted to acquiring biotech and biologic companies, whose products are “more complex, unpredictable and difficult and expensive to make,” than chemical-based medicine, Jones wrote.
Conventional drugs are chemically synthesized and have a known structure according to the U.S. Food and Drug Administration (FDA). Biologics come from living humans, animal or microorganism cells, and are technologically altered to target particular proteins or cells in the immune system. The FDA calls biologics “complex mixtures that are not easily identified or characterized.”
As a drug class, biologics offer an appealing solution to the patent cliff problem, because they can’t be easily replicated like generic versions of conventional drugs.
Instead, producers make “biosimilars,” which unlike genetics can’t simply be interchanged with the original drug during a course of treatment without serious safety risks, according to Jones. And while generics are cheap, biosimilars are still expensive to produce. There also are regulatory hurdles to getting biosimilars to market.
However, Jones wrote, the serious safety issues associated with biologics — the high risk of serious adverse events associated with the COVID-19 vaccine, for example — make it difficult for drugmakers to find commercial success in a conventional regulatory environment.
“Luckily for Big Pharma,” Jones wrote, the WHO and its private backers “are pursuing an unprecedented legal process that would cement loopholes that could solve these significant market challenges of at least some biotechnologies.”
Such loopholes made Pfizer and Moderna’s COVID-19 mRNA vaccines — the paradigmatic example of this new strategy — Big Pharma’s highest-selling annual market success ever.
Distribution of the COVID-19 vaccines to approximately 70% of people globally was possible only because of the “fast-tracked, deregulated development and mandated consumption of the experimental drugs,” Jones wrote.
The industry hopes to replicate that model with other drugs. And it has already begun — last month the Biomedical Advanced Research and Development Authority, or BARDA, gave Moderna $176 million to develop an mRNA bird flu vaccine.
Stakeholders behind the WHO have turned it into an arm of Big Pharma
According to Jones, the process of rapidly developed and mandated experimental drugs was first adopted by the U.S. military for bioweapons threats. Now, it is being internationally legitimized by the WHO through the agency’s revisions to the International Health Regulations (IHR) and its continued attempt to push its pandemic treaty.
The amendments were watered down and the treaty was partially thwarted at the last meeting of the World Health Assembly, which ended on June 1. However, the powers added to the amendments and the language in the treaty WHO and its backers are still hoping to advance next year show the type of biotech pandemic market Big Pharma has in the works.
According to Jones, this market:
Will not be one that depends on the free will of consumers to opt in and out of products — but instead relies on tactics of forced consumption and manipulation of regulatory paradigms.
At the forefront of this push are the WHO’s public-private-partners/private stakeholders, who directly shape and benefit from this policy. Their influence has, in effect, turned the WHO into an arm of Big Pharma, one so powerful that it already demonstrated its ability to morph the entire international regulatory process for the benefit of the pharmaceutical industry during the COVID-19 pandemic.
These stakeholders can wield this power in part because the WHO receives 80% of its funding from private stakeholders.
Those stakeholders include private-sector giants like Bill Gates, his public-private partnership organizations like the Coalition for Epidemic Preparedness Innovations (CEPI) and public-sector bureaucrats, such as Dr. Anthony Fauci and Rick Bright, Ph.D., of BARDA and the Rockefeller Foundation, who have been working for years to create a new system that would speed up vaccine production.
During the COVID-19 pandemic period, even states that lacked legal structures to provide emergency authorization for new drugs created them, using the WHO’s Emergency Use Listing Procedure (EUL) as justification, and aided by the WHO’s COVAX vaccine distribution system. COVAX was co-led by the WHO, Gavi, CEPI and Unicef, which are all backed by Gates.
The goal now, Jones wrote, is to institutionalize the procedures that were put in place globally for COVID-19 to pave the way for a new pandemic market.
The One Health agenda, which requires “full-scale surveillance of the human-animal environment,” both before and during pandemics, is central to this plan, he wrote.
The four pillars of the emerging pandemic market
There are four pillars to the plan for securing this market. The pillars are embodied in the WHO’s recently passed IHR amendments and the proposed pandemic treaty.
1. Biosurveillance of “pathogens with pandemic potential”: The WHO is calling on member states to create infrastructure to conduct biosurveillance on entire populations.
WHO private stakeholders, like the Wellcome Trust and the Bill & Melinda Gates Foundation, have been funding such initiatives for years and continue to be at the forefront of similar initiatives today, Jones wrote.
2. Rapid sharing of data and research: Under the IHR amendments, the WHO’s director-general must provide support for member states’ research and development. In the pending treaty, that would include helping them rapidly share data during a pandemic.
Such sharing should help coordinate global pandemic responses and also “pandemic prevention.” That means building a globally coordinated effort to research and share data on diseases that don’t currently pose a public health threat but are allegedly “likely to cause epidemics in the future.”
The WHO’s announcement last week that it is facilitating data-sharing for a new mRNA bird flu vaccine from Argentina is one example.
Experts have raised concerns that incentivizing such “preventive R&D” could incentivize risky gain-of-function research, Jones wrote.
Jones also noted that it is “highly likely” that the same global organizations that partner with the WHO and are funded by its largest private donors will be the ones doing this research and development on vaccines for “future pathogens with pandemic potential” — and also the ones profiting from it.
3. New regulatory pathways: The WHO is developing new regulatory pathways for unapproved medical products to get to market during pandemic emergencies. The IHR amendments are vague on this, Jones wrote, but the proposed language of the treaty aims to speed up emergency authorizations of WHO-recommended investigational “relevant health products.”
The proposed treaty also seeks to compel member countries to take steps to ensure they have the “legal, administrative and financial frameworks in place to support emergency regulatory authorizations for the effective and timely approval of pandemic-related health products during a pandemic.”
4. Global mandates of unapproved products: The final key element in the Big Pharma-WHO plan to pave the way for a new pandemic market is shoring up the global capacity to mandate unapproved medical products.
According to Jones, in July 2023, the WHO adopted the European Union’s (EU) digital COVID-19 passport system, or the “immunity pass” which recorded people’s vaccination records, negative test results or records of previous infections.
“While a digital vaccine passport does not function as a hard mandate in which every citizen of a given population is forced to take a vaccine, it acts as a conditional mandate — one which offers the illusion of choice, but — in reality — restricts the civil liberties of those who do not comply,” Jones wrote.
The 2005 version of the IHR allowed for travel-based mandates that required proof of vaccination to enter countries when there was a public health risk. The new IHR, Jones wrote, expands on this by detailing the kinds of technology that can be used to check such information during future pandemics.
The WHO also is developing its Global Digital Health Certification Network, which expands the EU digital passport system to a global scale. It will digitize vaccination records and health records and will be “interoperable” with existing networks.
While interoperability makes it possible for decentralized data to be shared globally, Jones wrote, “The UN is seeking to impose digital identification as a ‘human right,’ or rather as a condition for accessing other human rights, for the entire global citizenry by 2030, as established in its Sustainable Development Goal 16.9.”
The initiative seeks to provide people with a “trusted, verifiable way” to prove who they are in the physical world and online.
Verification systems of this size will place the right of citizens to do basic activities — like traveling, eating at a restaurant or working their job — in the hands of governments and potentially employers.
The rights of civilians will be conditional, dictated by data stored in a massive digital hub that is global in its sharing abilities. Not only will domestic governments have access to the health information of their own citizens under this system, but an entire global bureaucracy will as well.
This article was originally published by The Defender — Children’s Health Defense’s News & Views Website under Creative Commons license CC BY-NC-ND 4.0. Please consider subscribing to The Defender or donating to Children’s Health Defense.
Agriculture
Why is Canada paying for dairy ‘losses’ during a boom?
This article supplied by Troy Media.
Canadians are told dairy farmers need protection. The newest numbers tell a different story
Every once in a while, someone inside a tightly protected system decides to say the quiet part out loud. That is what Joel Fox, a dairy farmer from the Trenton, Ont., area, did recently in the Ontario Farmer newspaper.
In a candid open letter, Fox questioned why established dairy farmers like himself continue to receive increasingly large government payouts, even though the sector is not shrinking but expanding. For readers less familiar with the system, supply management is the federal framework that controls dairy production through quotas and sets minimum prices to stabilize farmer income.
His piece, titled “We continue to privatize gains, socialize losses,” did not come from an economist or a critic of supply management. It came from someone who benefits from it. Yet his message was unmistakable: the numbers no longer add up.
Fox’s letter marks something we have not seen in years, a rare moment of internal dissent from a system that usually speaks with one voice. It is the first meaningful crack since the viral milk-dumping video by Ontario dairy farmer Jerry Huigen, who filmed himself being forced to dump thousands of litres of perfectly good milk because of quota rules. Huigen’s video exposed contradictions inside supply management, but the system quickly closed ranks until now. Fox has reopened a conversation that has been dormant for far too long.
In his letter, Fox admitted he would cash his latest $14,000 Dairy Direct Payment Program cheque, despite believing the program wastes taxpayer money. The Dairy Direct Payment Program was created to offset supposed losses from trade agreements like the Comprehensive Economic and Trade Agreement (CETA), the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP) and the Canada–United States–Mexico Agreement (CUSMA).
During those negotiations, Ottawa promised compensation because the agreements opened a small share of Canada’s dairy market, roughly three to five per cent, to additional foreign imports. The expectation was that this would shrink the domestic market. But those “losses” were only projections based on modelling and assumptions about future erosion in market share. They were predictions, not actual declines in production or demand. In reality, domestic dairy demand has strengthened.
Which raises the obvious question: why are we compensating dairy farmers for producing less when they are, in fact, producing more?
This month, dairy farmers received another one per cent quota increase, on top of several increases totalling four to five per cent in recent years. Quota only goes up when more milk is needed.
If trade deals had actually harmed the sector, quota would be going down, not up. Instead, Canada’s population has grown by nearly six million since 2015, processors have expanded and consumption has held steady. The market is clearly expanding.
Understanding what quota is makes the contradiction clearer. Quota is a government-created financial asset worth $24,000 to $27,000 per kilogram of butterfat. A mid-sized dairy farm may hold about $2.5 million in quota. Over the past few years, cumulative quota increases of five per cent or more have automatically added $120,000 to $135,000 to the value of a typical farm’s quota, entirely free.
Larger farms see even greater windfalls. Across the entire dairy system, these increases represent hundreds of millions of dollars in newly created quota value, likely exceeding $500 million in added wealth, generated not through innovation or productivity but by a regulatory decision.
That wealth is not just theoretical. Farm Credit Canada, a federal Crown corporation, accepts quota as collateral. When quota increases, so does a farmer’s borrowing power. Taxpayers indirectly backstop the loans tied to this government-manufactured asset. The upside flows privately; the risk sits with the public.
Yet despite rising production, rising quota values, rising equity and rising borrowing capacity, Ottawa continues issuing billions in compensation. Between 2019 and 2028, nearly $3 billion will flow to dairy farmers through the Dairy Direct Payment Program. Payments are based on quota holdings, meaning the largest farms receive the largest cheques. New farmers, young farmers and those without quota receive nothing. Established farms collect compensation while their asset values grow.
The rationale for these payments has collapsed. The domestic market did not shrink. Quota did not contract. Production did not fall. The compensation continues only because political promises are easier to maintain than to revisit.
What makes Fox’s letter important is that it comes from someone who gains from the system. When insiders publicly admit the compensation makes no economic sense, policymakers can no longer hide behind familiar scripts. Fox ends his letter with blunt honesty: “These privatized gains and socialized losses may not be good for Canadian taxpayers … but they sure are good for me.”
Canada is not being asked to abandon its dairy sector. It is being asked to face reality. If farmers are producing more, taxpayers should not be compensating them for imaginary declines. If quota values keep rising, Ottawa should not be writing billion-dollar cheques for hypothetical losses.
Fox’s letter is not a complaint; it is an opportunity. If insiders are calling for honesty, policymakers should finally be willing to do the same.
Dr. Sylvain Charlebois is a Canadian professor and researcher in food distribution and policy. He is senior director of the Agri-Food Analytics Lab at Dalhousie University and co-host of The Food Professor Podcast. He is frequently cited in the media for his insights on food prices, agricultural trends, and the global food supply chain.
Troy Media empowers Canadian community news outlets by providing independent, insightful analysis and commentary. Our mission is to support local media in helping Canadians stay informed and engaged by delivering reliable content that strengthens community connections and deepens understanding across the country.
Agriculture
Canadians should thank Trump for targeting supply management
This article supplied by Troy Media.
By Gwyn Morgan
Trump is forcing the Canadian government to confront what it has long avoided: an end to supply management
U.S. President Donald Trump’s deeply harmful tariff rampage has put the Canada-U.S.-Mexico Agreement (CUSMA) under renewed strain. At the centre of that uncertainty is Canada’s supply management system, an economically costly and politically protected regime Ottawa has long refused to reform.
Supply management uses quotas and fixed prices for milk, eggs and poultry with the intention of matching supply with demand while restricting imports. Producers need quota in order to produce and sell output legally. Given the thousands of farmers spread across the country, combined with the fact that the quotas are specific to milk, eggs, chickens and turkey, the bureaucracy (and number of bureaucrats) required is huge and extremely costly. Department of Agriculture and Agri-Food 2024-25 transfer payments included $4.8 billion for “Supply Management Initiatives.”
The bureaucrats often get it wrong. Canada’s most recent chicken production cycle saw one of the worst supply shortfalls in more than 50 years. Preset quota limits stopped farmers from responding to meet demand, leaving consumers with higher grocery bills for 11th-hour imports. The reality is that accurately predicting demand is impossible.
The dysfunction doesn’t stop with chicken. Egg imports under the shortage allocation program had already topped 14 million dozen by mid-year. Our trading partners are taking full advantage. Chile, for example, is on track to double chicken exports.
The cost to consumers is considerable. Pre-pandemic research estimates the average Canadian family pays $300 to $444 extra for food as a result of supply management. And since, as a share of their income, lower-income Canadians spend three times as much as middle-income Canadians and almost five times as much as upper-income Canadians, the impact on them is proportionally much greater.
It’s no surprise that farmers are anxious to protect their monopoly. In most cases, they have paid hefty sums for their quota. If the price of their product were allowed to fall to free-market levels, the value of their quota would go to zero. In addition, the Dairy Farmers of Canada argue that supply management means “the right amount of food is produced,” producers get a “fair return,” and import restrictions guarantee access to “homegrown food,” all of which is debatable.
All price-fixing systems create problems. Dairy cattle are not machines. A cow’s milk production varies. If a farmer gets more milk than his quota, the excess must be dumped. When governments limit the supply of any item, its value always rises. Dairy quotas, by their very nature, have become a valuable commodity, selling for more than $25,000 per “cow equivalent.” That means a 100-head dairy farm is worth at least $2,500,000 in quota alone, a value that exists only because of the legislated ability to charge higher-than-market prices.
Dairy isn’t the only sector where government-regulated quotas have become very valuable. The West Coast fishery is another. Commercial fishery quotas for salmon and halibut have become valuable commodities worth millions of dollars, completely out of reach for independent fishers, turning them into de facto employees of quota holders.
While of relatively limited national importance, supply management is of major political significance in Quebec. As George Mason University and Montreal Economic Institute economist Vincent Geloso notes, “In 17 ridings provincially, people under supply management are strong enough to change the outcome of the election.”
That brings us back to the upcoming CUSMA negotiations. Under CUSMA, the U.S. gets less than five per cent of Canada’s agricultural products market. Given that President Trump has been a long-standing critic of supply management, especially in dairy, it’s certain to be targeted.
Looking to pre-empt concessions, supply-managed farmer associations lobbied the federal government to pass legislation keeping supply management off the table in any future trade negotiations. This makes voters in those 17 Quebec ridings happy, but it’s certain to enrage Trump, starting the CUSMA negotiations off on a decidedly adversarial note. As Concordia University economist Moshe Lander says: “The government seems willing even to accept tariffs and damage to the Canadian economy rather than put dairy supply management on the table.”
Parliament can pass whatever laws it likes, but Trump has made it clear that ending supply management, especially in dairy, is one of his main goals in the CUSMA review. It’s hard to see how a deal can be made without substantial reform. That will make life difficult for the federal Liberals. But the president will be doing Canadian consumers a big favour.
Gwyn Morgan is a retired business leader who has been a director of five global corporations.
Troy Media empowers Canadian community news outlets by providing independent, insightful analysis and commentary. Our mission is to support local media in helping Canadians stay informed and engaged by delivering reliable content that strengthens community connections and deepens understanding across the country.
-
Daily Caller2 days agoParis Climate Deal Now Decade-Old Disaster
-
Business1 day agoOttawa Pretends To Pivot But Keeps Spending Like Trudeau
-
International2 days agoFBI didn’t think it had cause to raid Trump but DOJ did it anyway
-
Energy1 day agoLiberals Twisted Themselves Into Pretzels Over Their Own Pipeline MOU
-
Censorship Industrial Complex1 day agoHow Wikipedia Got Captured: Leftist Editors & Foreign Influence On Internet’s Biggest Source of Info
-
Indigenous2 days agoResidential school burials controversy continues to fuel wave of church arsons, new data suggests
-
Alberta2 days agoAlberta’s huge oil sands reserves dwarf U.S. shale
-
Daily Caller2 days agoHegseth Planning Huge Shakeup Of Top Military Command: REPORT


